亘喜生物：2022年全年未经审计的财务业绩及运营最新进展公布

 收藏

关键词：生物

资讯来源：生物药大时代

发布时间： 2023-03-15

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。

本期热点

中国苏州、上海/美国加利福尼亚州圣迭戈

2023年3月14日

➤ 2023年1月，FasTCAR-T GC012F针对复发/难治性多发性骨髓瘤（RRMM）适应症的新药临床试验（IND）申请获得美国FDA批准，公司计划于2023年第二季度在美国启动1b/2期临床试验

➤ 同年2月，FasTCAR-T GC012F针对RRMM适应症的IND申请同样获得中国国家药品监督管理局（NMPA）批准，公司将如期在2023年第三季度在中国启动1/2期临床试验

➤ 稳步推进评估FasTCAR-T GC012F针对复发/难治性B细胞非霍奇金淋巴瘤（r/r B-NHL）IIT研究的患者入组及临床随访工作

➤ 计划于2023年上半年在中国如期启动SMART CAR-T GC506针对Claudin18.2阳性实体瘤的IIT研究

➤ 充裕的现金流可保障公司日常的研发及运营至2024年底

亘喜生物科技集团（简称“亘喜生物”或“公司”；纳斯达克股票代码：GRCL）一家致力于开发高效、经济的细胞疗法用于癌症治疗的全球临床阶段生物制药公司，公布了截至2022年12月31日的2022年第四季度和全年未经审计的财务业绩，以及公司运营的最新进展。

</section></section><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 0px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;font-size: 0px;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 406.198px;vertical-align: top;flex: 0 0 auto;height: auto;align-self: flex-start;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 5px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(230, 70, 35);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section></section><section powered-by="xiumi.us" style="margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: right;justify-content: flex-end;font-size: 0px;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 406.198px;vertical-align: top;flex: 0 0 auto;height: auto;align-self: flex-start;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 5px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(215, 213, 213);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section></section><section powered-by="xiumi.us" style="margin-bottom: 0px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;font-size: 12px;color: rgb(164, 164, 164);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgba(255, 255, 255, 0);overflow-wrap: break-word !important;">点击观看亘喜生物</span></strong></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgba(255, 255, 255, 0);overflow-wrap: break-word !important;"><2022全年财务业绩及企业最新进展></span></strong></p></section><p powered-by="xiumi.us" style="margin-bottom: 0px;outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.3444444" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/BCdthRictH1wvjRqHwQwO7KLicuMreRPdwVhAJwnpExLaBUsaIznQqhyKICyzH75QFTLl6UOTOacp5qhxicJBx64g/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="jpeg" data-w="1080" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 677px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section><section powered-by="xiumi.us" style="margin-top: 20px;margin-bottom: 20px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="padding-right: 10px;padding-left: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;min-width: 10%;vertical-align: top;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="padding: 3px 10px 6px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;min-width: 10%;vertical-align: top;border-width: 1px;border-style: solid none;border-color: rgb(234, 234, 234) rgb(62, 62, 62);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: -20px;margin-bottom: -5px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;overflow-wrap: break-word !important;"><section style="padding-right: 5px;padding-left: 5px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 40px;height: 40px;vertical-align: top;overflow: hidden;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;width: 30px;height: auto;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.6437768" data-src="https://mmbiz.qpic.cn/mmbiz_svg/BA8GZZ2EGwX01fKy4EJkNcpwDJGexHgIibCqhBnStjM2DaHD5AYlLwibA5fibb95yVsabXfMsIjvIhsq1lKUkAy0hsPb5BvWjVI/640?wx_fmt=svg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="svg" data-w="233" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 30px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;text-align: justify;color: rgb(62, 62, 62);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;">2022年，公司在诸多方面取得积极进展。尤其是我们的核心候选产品BCMA/CD19双靶点FasTCAR-T细胞疗法GC012F在横跨3项适应症、针对48名患者的临床试验中展现出了<strong style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;">令人振奋的有效性</strong>和<strong style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;">独具优势的安全性</strong>。这使我们进一步深信GC012F针对多种血液学和免疫学适应症，具备<strong style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;">显著的临床潜力</strong>。随着近期GC012F的IND申请连续获得美国FDA和中国NMPA的批准，未来几个月内，我们计划在中美如期开展这两项针对RRMM正式临床试验的入组工作，此外，我们计划在2023年年中公布关键的临床数据，以进一步展示GC012F针对RRMM<strong style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;">持久应答</strong>的疗效。与此同时，我们也在大力推进其他技术平台的研发，不断扩充我们的临床产品管线，包括将于2023年上半年在中国启动SMART CAR-T GC506针对Claudin18.2阳性实体瘤的IIT研究。</p></section></section><section powered-by="xiumi.us" style="margin-bottom: -30px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: right;overflow-wrap: break-word !important;"><section style="padding-right: 5px;padding-left: 5px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 40px;height: 35px;vertical-align: top;overflow: hidden;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;transform: rotateX(180deg);line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;width: 30px;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.6437768" data-src="https://mmbiz.qpic.cn/mmbiz_svg/BA8GZZ2EGwX01fKy4EJkNcpwDJGexHgIFhMJAuFXtBdbicsd2EIS9SiaYE0I187R7oz9fDlTaOiaTJQrDfiabgJLbJxRN7ia87iaMw/640?wx_fmt=svg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="svg" data-w="233" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 30px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section></section></section></section></section></section></section><p powered-by="xiumi.us" style="margin-bottom: 0px;outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: top;overflow-wrap: break-word !important;"><section style="margin-bottom: -6px;padding-right: 2px;padding-left: 2px;outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 1em;font-size: 18px;color: rgb(160, 160, 160);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">产品管线亮点</strong></p></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;width: 115.271px;height: 10px;background-color: rgba(240, 221, 217, 0.43);overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section powered-by="xiumi.us" style="margin-top: -7px;margin-bottom: -7px;outline: 0px;max-width: 100%;box-sizing: border-box;transform: scale(0.97);transform-origin: center center;overflow-wrap: break-word !important;"><section style="margin-top: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.1953704" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/BCdthRictH1wvjRqHwQwO7KLicuMreRPdwdO2wbbxPjPI20ZuDYMxPcTdLaAnjHEa4oFYLWWGFezJiaevTpCjHRMA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="jpeg" data-w="1080" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 677px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section><section powered-by="xiumi.us" style="margin-bottom: -12px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;border-width: 2px;border-style: solid;border-color: rgb(255, 151, 75);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(62, 62, 62);text-align: center;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">可实现“次日生产完毕”的自体CAR-T细胞疗法</strong></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">细胞健康状态得到强化</strong></p></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 15px 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 653px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;border-color: rgb(236, 121, 51);border-width: 2px;border-style: none;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: -20px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(255, 151, 75);font-size: 25px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">GC012F</strong></p></section></section><section powered-by="xiumi.us" style="margin-top: -5px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(106, 106, 106);text-align: justify;font-size: 12px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(236, 121, 51);font-size: 14px;overflow-wrap: break-word !important;">B细胞成熟抗原（BCMA）/CD19双靶点自体CAR-T候选产品，目前正在相关临床研究中评估其治疗RRMM、NDMM和B-NHL的安全性和有效性。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 13px;color: rgb(255, 151, 75);overflow-wrap: break-word !important;">○ </span><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">计划于2023年第二季度在美国启动GC012F针对RRMM的1b/2期IND临床试验。</span></strong></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ <span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">2023年1月，公司在美国提交的IND申请得到FDA批准。</span></span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ <span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">1b期临床试验旨在评估GC012F两种剂量治疗约12名患者的安全性和耐受性，并确定GC012F的2期临床试验推荐剂量（RP2D）。</span></span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ </span><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);font-size: 14px;overflow-wrap: break-word !important;">基于目前试验方案，2期临床试验旨在评估GC012F治疗约50名患者的有效性，并进一步明确其安全性。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 13px;color: rgb(255, 151, 75);overflow-wrap: break-word !important;">○ </span><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">计划于2023年第三季度在中国启动GC012F针对RRMM的1/2期IND临床试验。</span></strong></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ <span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">2023年2月，公司在中国提交的IND申请获得NMPA批准。</span></span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ </span><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">1期临床试验旨在评估GC012F两种剂量治疗约9名患者的安全性和耐受性，并确定GC012F的2期RP2D。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ </span><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(164, 164, 164);font-size: 14px;overflow-wrap: break-word !important;">基于目前试验方案，2期临床试验旨在评估GC012F治疗约98名患者的有效性，并进一步明确其安全性。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 13px;color: rgb(255, 151, 75);overflow-wrap: break-word !important;">○</span><a data-itemshowtype="0" data-linktype="2" hasload="1" href="http://mp.weixin.qq.com/s?__biz=MzkzNDMyOTA5Mw==&mid=2247487576&idx=1&sn=65c923dfc09c7fa97bf824a06dac5ad8&chksm=c2bfbe32f5c837243a516eee874718337077288231bc5f5be717c387462e147e7ccadfac48a2&scene=21#wechat_redirect" imgdata="null" imgurl="" linktype="text" style="outline: 0px;-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;" tab="innerlink" target="_blank" textvalue="2022年ASH年会"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">2022年ASH年会</span></strong></a><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">期间，公司公布了一项正在开展的由研究发起的临床试验（IIT）的首次人体试验数据，以评估GC012F针对符合移植条件、高危的多发性骨髓瘤新确诊患者（NDMM）的效果。</span></strong></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(160, 160, 160);overflow-wrap: break-word !important;">○ </span><a data-itemshowtype="0" data-linktype="2" hasload="1" href="http://mp.weixin.qq.com/s?__biz=MzkzNDMyOTA5Mw==&mid=2247487939&idx=1&sn=f7fb6bf22dd39ea150fa3829e31485e7&chksm=c2bfbfa9f5c836bfe7b4a0fe4b841c787843588fd979398f2cb04267d0a99361342c32178bc7&scene=21#wechat_redirect" imgdata="null" imgurl="" linktype="text" style="outline: 0px;-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;" tab="innerlink" target="_blank" textvalue="结果显示"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">结果显示</span></a><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">，在所有剂量水平下，16名接受了GC012F单次输注治疗的患者，达到了100%总体应答率（ORR）和100%微小残留病灶阴性（MRD-）的优异疗效。75%接受治疗的患者未出现任何级别的细胞因子释放综合征。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">○ </span><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(164, 164, 164);overflow-wrap: break-word !important;">公司将稳步推进该项IIT研究，继续患者入组及临床随访工作。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 13px;color: rgb(255, 151, 75);overflow-wrap: break-word !important;">○ </span><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">在中国，将继续开展GC012F针对r/r B-NHL的IIT研究，持续推进患者入组及临床随访工作。</span></strong></p></section></section></section></section></section></section></section></section></section><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 15px;outline: 0px;max-width: 100%;box-sizing: border-box;display: flex;flex-flow: row nowrap;text-align: center;justify-content: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: 223.406px;flex: 0 0 auto;align-self: center;height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 0.5em;margin-bottom: 0.5em;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(234, 234, 234);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;line-height: 0;align-self: center;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 8px;height: 8px;vertical-align: top;overflow: hidden;background-color: rgb(234, 234, 234);overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: 223.406px;flex: 0 0 auto;align-self: center;height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 0.5em;margin-bottom: 0.5em;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(234, 234, 234);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section></section><section powered-by="xiumi.us" style="margin-top: -11px;margin-bottom: -11px;outline: 0px;max-width: 100%;box-sizing: border-box;transform: scale(0.97);transform-origin: center center;overflow-wrap: break-word !important;"><section style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.2027778" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/BCdthRictH1wvjRqHwQwO7KLicuMreRPdwxkDAKeYHC5YXf2wLx8Lk841soFicHXvyaFDLysUp3WAbMFfCAjDO6DQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="jpeg" data-w="1080" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 677px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;border-width: 2px;border-style: solid;border-color: rgb(68, 158, 189);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(255, 251, 251);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">创<span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(62, 62, 62);font-size: 16px;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">创新设计的"即用型"</strong></span></span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(62, 62, 62);overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">同种异体CAR-T细胞疗法</strong></span></p></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 15px 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 653px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;border-style: none;border-width: 2px;border-color: rgb(68, 158, 189);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: -20px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(68, 158, 189);font-size: 25px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">GC502</strong></p></section></section><section powered-by="xiumi.us" style="margin-top: -5px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(106, 106, 106);text-align: justify;font-size: 12px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(68, 158, 189);font-size: 14px;overflow-wrap: break-word !important;">基于TruUCAR平台开发的CD19/CD7双靶向同种异体CAR-T细胞疗法，目前正在中国开展一项IIT 1期临床研究，评估其治疗B细胞恶性血液肿瘤的安全性和有效性。GC502使用来自无需人类白细胞抗原（HLA）匹配的健康供者的T细胞进行制备。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 13px;color: rgb(68, 158, 189);overflow-wrap: break-word !important;">○</span><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(68, 158, 189);overflow-wrap: break-word !important;"> </span><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">在<a data-itemshowtype="0" data-linktype="2" hasload="1" href="http://mp.weixin.qq.com/s?__biz=MzkzNDMyOTA5Mw==&mid=2247485743&idx=1&sn=91fe745c1d25eddd56042ce3dba7bdc4&chksm=c2bfa745f5c82e5301487fae9a6cc143492618b03fa16ee4bbd983a947735e6ae4f075306ab4&scene=21#wechat_redirect" imgdata="null" imgurl="" linktype="text" style="outline: 0px;-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;" tab="innerlink" target="_blank" textvalue="EHA2022">EHA2022</a>年会期间公布了GC502治疗r/r B-ALL的一项单臂、开放性IIT研究的长期随访数据。</span></strong></p></section></section></section></section></section></section></section></section></section><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: flex;flex-flow: row nowrap;text-align: center;justify-content: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: 223.406px;flex: 0 0 auto;align-self: center;height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 0.5em;margin-bottom: 0.5em;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(234, 234, 234);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;line-height: 0;align-self: center;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 8px;height: 8px;vertical-align: top;overflow: hidden;background-color: rgb(234, 234, 234);overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: 223.406px;flex: 0 0 auto;align-self: center;height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 0.5em;margin-bottom: 0.5em;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(234, 234, 234);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section></section><section powered-by="xiumi.us" style="margin-top: -6px;margin-bottom: -6px;outline: 0px;max-width: 100%;box-sizing: border-box;transform: scale(0.97);transform-origin: center center;overflow-wrap: break-word !important;"><section style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.187037" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/BCdthRictH1wvjRqHwQwO7KLicuMreRPdwM8PxYwZcG5ibFNUfSBlBpmKb1g1uickiaibDJOR4k0mJ3Xw4tMG7eoDlJw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="jpeg" data-w="1080" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 677px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;border-style: solid;border-width: 2px;border-color: rgb(255, 202, 0);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(62, 62, 62);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">依托于独特的结构设计，<strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(255, 177, 44);overflow-wrap: break-word !important;">SMART CART<sup style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">TM</sup></span></strong>能通过利用并扭转肿瘤微环境（TME）的抑制性信号，进而有效地攻击实体瘤；基于该技术模块打造的产品旨在强化CAR-T细胞的扩增能力及持续杀伤肿瘤的能力，并通过改善CAR-T细胞的持久性以延缓耗竭。</span></p></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 15px 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 653px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(106, 106, 106);text-align: justify;font-size: 13px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(255, 202, 0);overflow-wrap: break-word !important;">○ </span><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">计划于2023年上半年，在中国启动一项GC506针对Claudin 18.2阳性实体瘤的IIT研究。</span></strong></p></section></section></section></section></section></section></section></section></section><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: flex;flex-flow: row nowrap;text-align: center;justify-content: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: 223.406px;flex: 0 0 auto;align-self: center;height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 0.5em;margin-bottom: 0.5em;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(234, 234, 234);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;line-height: 0;align-self: center;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 8px;height: 8px;vertical-align: top;overflow: hidden;background-color: rgb(234, 234, 234);overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: 223.406px;flex: 0 0 auto;align-self: center;height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-top: 0.5em;margin-bottom: 0.5em;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(234, 234, 234);height: 1px;overflow-wrap: break-word !important;"><svg style="float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1"/></section></section></section></section><section powered-by="xiumi.us" style="margin-top: -4px;margin-bottom: -4px;outline: 0px;max-width: 100%;box-sizing: border-box;transform: scale(0.97);transform-origin: center center;overflow-wrap: break-word !important;"><section style="margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;line-height: 0;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="0.2231481" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/BCdthRictH1wvjRqHwQwO7KLicuMreRPdwIVybicDzPuzgs4d8uVzicVFs4mg3vhHtnlj4AJXeSibialjsuSbURw4WNQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="jpeg" data-w="1080" style="outline: 0px;box-sizing: border-box;vertical-align: middle;width: 677px;overflow-wrap: break-word !important;visibility: visible !important;"/></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 677px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;border-style: solid;border-width: 2px;border-color: rgb(6, 63, 93);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(62, 62, 62);font-size: 13px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">靶向CD19、HLA匹配供者来源的异基因CAR-T细胞疗法，用于治疗经同种异体干细胞移植后失败，且不符合自体CAR-T疗法的r/r B-ALL患者。</span></p></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-start;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="padding: 15px 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 653px;vertical-align: top;align-self: flex-start;flex: 0 0 auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(106, 106, 106);text-align: justify;font-size: 13px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(6, 63, 93);overflow-wrap: break-word !important;">○ </span><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;overflow-wrap: break-word !important;">评估GC007g治疗r/r B-ALL的1/2期注册性临床试验的2期研究阶段继续进行中。</span></strong></p></section></section></section></section></section></section></section></section></section><p><br/></p><p><span style="font-size: 12px;">文章来源：<span style="font-size: 12px;color: rgb(51, 51, 51);letter-spacing: normal;text-decoration: none;">亘喜生物</span></span><span style="text-align: center;"/></p><p style="display: none;"><mp-style-type data-value="3"/></p></div>